Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Dermatitis
Description
Any inflammation of the skin. MeSH
Hierarchy View
Subtype Terms (13)
Dermatitis, Atopic
326 drugs (108 approved, 218 experimental)
Dermatitis, Contact
19 drugs (10 approved, 9 experimental)
Dermatitis, Exfoliative
3 approved drugs
Dermatitis Herpetiformis
9 drugs (7 approved, 2 experimental)
Dermatitis, Perioral
3 approved drugs
Dermatitis, Seborrheic
28 drugs (19 approved, 9 experimental)
Eczema
107 drugs (48 approved, 59 experimental)
Intertrigo
3 approved drugs
Neurodermatitis
6 drugs (4 approved, 2 experimental)
Radiodermatitis
29 drugs (12 approved, 17 experimental)
Approved Indicated Drugs (5)
Phase 4 Indicated Drugs (1)
Organization Involved with Phase 4 Indications (82)
1st Allergy & Clinical Research Center
Atopic Dermatitis Research Network
Bernstein Clinical Research Center
Dell Children's Medical Center
Hoosier Cancer Research Network
Icahn School of Medicine at Mount Sinai
National Institute for Health Research, United Kingdom
National Institute of Allergy and Infectious Diseases (NIAID)
Oregon Health and Science University
Society for Pediatric Dermatology
St. Luke's-Roosevelt Hospital Center
Technical University of Dresden
The Center for Clinical and Cosmetic Research
Organization Involved with Phase 3 Indications (78)
Gottfried Wilhelm Leibniz Universität Hannover
Hospital Padre Bento de Guarulhos
Kolderma Instituto De Pesquisa Clinica
Korea Research Institute of Bioscience & Biotechnology
Luigi Sacco University Hospital
National Cancer Institute (NCI)
National Hepatology & Tropical Medicine Research Institute
North Central Cancer Treatment Group
Novum Pharmaceutical Research Services
Spartanburg Regional Medical Center
St. Antonius Hospital, Nieuwegein
Organization Involved with Phase 2 Indications (189)
Associated Skin Care Specialists
Badalona Hospital Germans Trias i Pujol
BioMimetix Pharmaceutical, Inc.
Centre de Recherche Dernatologique du Quebec
Consortium of Food Allergy Research
Forest Hills Dermatology Group
Guangzhou Four-Leaf Clover HealthTech Co., Ltd.
Hemay Pharmaceutical PTY. LTD.
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hospital Universitario Virgen Macarena
Huazhong University of Science and Technology
Instituto Dermatologico y Cirugia de Piel
Iran University of Medical Sciences
Mayanei Hayeshua Medical Center
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Polytechnic Institute, Mexico
Provectus Biopharmaceuticals, Inc.
Reistone Biopharma Company Limited
Rochester Skin Lymphoma Medical Group, PLLC
Shulov Innovate for Science Ltd.
Suzhou Connect Biopharmaceuticals
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Technical University of Munich
Texas Dermatology and Laser Specialists
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universitaetsklinikum Schleswig-Holstein
University of Colorado, Denver
University of Medicine and Dentistry of New Jersey
Organization Involved with Phase 1 Indications (36)
Organization Involved with Other Experimental Indications (72)
All India Institute of Medical Sciences
Association pour la Recherche Clinique et Immunologique
Chinese Academy of Medical Sciences
Clinica Pediatrica Ospedale dei Bambini Vittore Buzzi
Cornerstone Naturopathic Clinic Inc.
Cosmetique Active International
Genesys Regional Medical Center
German Federal Ministry of Education and Research
Hospital General Dr. Manuel Gea Gonzalez
Hospital Universitario Reina Sofía
Institut National de la Santé Et de la Recherche Médicale, France
Norwegian University of Science and Technology
Ospedale dei Bambini V. Buzzi Milano
Pontificia Universidad Catolica de Chile
Skin Investigation and Technology Hamburg GmbH
South African Medical Association
Spartanburg Regional Family Medicine
Swiss National Science Foundation
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.